From: Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Number of Patients (%) | ||||||
---|---|---|---|---|---|---|
SAXA 2.5 mg (n = 937) |
SAXA 5 mg (n = 1269) |
SAXA 10 mg (n = 1000) |
All SAXA* (n = 3356) |
Controls (n = 1251) |
Hazard Ratio (95% CI)† | |
Investigator-reported MACE | 6 (0.6) | 6 (0.5) | 11 (1.1) | 23 (0.7) | 18 (1.4) |
0.44 (0.2-0.82) |
Adjudicated MACE | 6 (0.6) | 7 (0.6) | 9 (0.9) | 22 (0.7) | 18 (1.4) |
0.42 (0.23-0.80) |
Myocardial infarction‡ Stroke‡ Other CV deaths§ |
2 (0.2) 4 (0.4) 0 (0) |
4 (0.3) 4 (0.3) 0 (0) |
2 (0.2) 3 (0.3) 4 (0.4) |
8 (0.2) 11 (0.3) 4 (0.1) |
8 (0.6) 5 (0.4) 6 (0.5) | |
All deaths | 3 (0.3) | 3 (0.2) | 4 (0.4) | 10 (0.3) | 12 (1.0) | |
CV deaths|| | 1 (0.1) | 2 (0.2) | 4 (0.4) | 7 (0.2) | 10 (0.8) |